Oral drug combination eases treatment burden for AML patients
June 04, 2026
June 04, 2026
ITHACA, New York, June 4 -- Cornell University posted the following news:
* * *
Oral drug combination eases treatment burden for AML patients
*
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
In the international phase 1/ . . .
* * *
Oral drug combination eases treatment burden for AML patients
*
The ASCERTAIN V clinical trial demonstrated that an all-oral drug combination for older patients with acute myeloid leukemia (AML) is an effective alternative to the current standard, which requires repeated hospital or office visits for intravenous treatment.
In the international phase 1/ . . .